medigraphic.com
ISSN 1684-1824 (Digital)

2012, Número 4

<< Anterior Siguiente >>

Rev Méd Electrón 2012; 34 (4)


Quimioprofilaxis en la recidiva tumoral vesical

Ruiz RRE, Crespo CL, Tejeda CY

Idioma: Español
Referencias bibliográficas: 40
Paginas: 439-449
Archivo PDF: 86.82 Kb.


RESUMEN

Los tumores vesicales superficiales se caracterizan por una alta tasa de recidiva, que ocurre especialmente dentro de los dos primeros años, y que es aun mayor en los grupos de alto riesgo. Existe consenso en la utilidad del uso del Bacilo de Calmette-Guerin para disminuir la recurrencia tumoral. La quimioterapia intravesical con otros medicamentos han demostrado su utilidad o no en disminuir la recurrencia de estos tumores vesicales. Entre los años 1999 y 2008 se estudian y tratan 110 pacientes (96 hombres y 14 mujeres), con una edad promedio de 63 años, divididos en tres grupos para tratamiento de la recidiva tumoral después de resección transuretral o cistectomía parcial, con tres diferentes agentes quimioprofilácticos e inmunomoduladores (Thio-Tepa, BCG+factor de transferencia, doxorrubicina+interferón alfa 2b). El objetivo de esta investigación fue presentar la experiencia en el tratamiento de estos pacientes, donde se observa mejores resultados en 5 años, con el grupo tratado con doxorrubicina+interferón alfa 2b, seguido del grupo tratado con BCG+factor de transferencia, con una marcada disminución de las recurrencias y una limitación en la progresión de la enfermedad a largo plazo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Aldousari S, Kassouf W. Update on the management on non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56-64. Citado en PubMed; PMID: 20165581.

  2. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatment of bladder cancer: review. Pharm Res. 2008;25(7):1500-10. Citado en PubMed; PMID: 18369709.

  3. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol. 2008;10(4):281-89. Citado en PubMed; PMID: 19145271.

  4. Schenk-Braat EA, Bangma CH. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother. 2005;54(51):14-23. Citado en PubMed; PMID: 15565330.

  5. Horn Y, Eidelman A, Walach N, Yuval E, Markowitz A. Treatment of superficial bladder tumors in a controlled trial with thio-TEPA versus adriamycin. J Surg Oncol. 1984;27(1):67-9. Citado en PubMed; PMID: 6434883.

  6. García Rodríguez J, Fernández Gómez JM, Barmadah SE, Álvarez Mujica M, Rodríguez Robles L, Martín Benito JL, et al. Terapia endovesical: influencia sobre la progresión en el cáncer vesical superficial. Arch Esp Urol [Internet]. 20007 [citado 23 Abr 2012]; 60(1). Disponible en: http://scielo.isciii.es/scielo.php?pid=S0004-06142007000100005&script=sci_arttext.

  7. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314-30. Citado en PubMed; PMID: 17993339.

  8. Hinotsu S, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, et al. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin]. Gan To Kagaku Ryoho. 2002 Jan;29(1):73-80. Citado en PubMed; PMID: 11816482.

  9. Gad el Mawla N, Mansour MA, Eissa S, Ali NM, Elattar I, Hamza MR, et al. A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder. Ann Oncol. 1991;2:137-40. Citado en PubMed; PMID: 2054316.

  10. Liu B, Wang Z, Chen B, Yu J, Zhang P, Ding Q, et al. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes. Cancer Invest. 2006;24:160-3. Citado en PubMed; PMID: 16537185.

  11. Kurth K, Tunn U, Ay R, Schröder FH, Pavone-Macaluso M, Debruyne F, et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol. 1997;158(2):378-84. Citado en PubMed; PMID: 9224307.

  12. Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L. The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study. Eur Urol. 2001;39(1):643-7. Citado en PubMed; PMID: 11464052.

  13. Patterson AL, Greenberg RE, Weems L, Bahnson R, Wajsman Z, Israel M, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2006;56(2):232-5. Citado en PubMed; PMID: 10925084.

  14. Uchio EM, Linehan WM, Figg WD, Walther MM. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder. J Urol. 2003;169(1):357-60. Citado en PubMed; PMID: 12478189.

  15. Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer. 2005;92(12):2140-7. Citado en PubMed; PMID: 15928663.

  16. Ecke TH, Bartel P, Koch S, Ruttloff J, Theissig F. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Oncol Rep. 2006;16(6):1381-8. Citado en PubMed; PMID: 17089065.

  17. Stavropoulos NE, Hastazeris K, Filiadis I, Mihailidis I, Ioachim E, Liamis Z, et al. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer--results of a controlled prospective study. Scand J Urol Nephrol. 2002;36(3):218-22. Citado en PubMed; PMID: 12201939.

  18. Joudi FN, Smith BJ, O'Donnell MA; National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006 Jul-Aug;24(4):344-8. Citado en PubMed; PMID: 16818189.

  19. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008;15(4):309-13. Citado en PubMed; PMID: 18380817.

  20. Clinton SK, Canto E, O'Donnell MA. Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am. 2000 Feb;27(1):147-55. Citado en PubMed; PMID: 10696253.

  21. Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother. 2003;26(4):343-8. Citado en PubMed; PMID: 12843796.

  22. Malkowicz SB. The role of intravesical chemotherapy in the treatment of bladder cancer. En: Lerner SP, Schoenberg M, Sternberg C, editors. Textbook of bladder cancer. London: T&F-Informa; 2006. p. 335-40.

  23. Lee C, Park MS. Prophylactic treatment of superficial bladder tumor. Int J Urol. 1998;5(6):511-20. PubMed; PMID 9855117.

  24. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001;166(4):1300-05. Citado en PubMed; PMID: 11547062.

  25. Witjes JA Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance? Urol Oncol. 2009; 27(3):322-4. Citado en PubMed; PMID: 19414122.

  26. Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycn C chemotherapy regiment in patients with non- muscle invasive bladder cancer. Urol Oncol. 2010; 28(5):510-4. Citado en PubMed; PMID: 19171491.

  27. Lam JS, Benson MC, O'Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH, et al. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol. 2003; 21(5):354-60. Citado en PubMed; PMID: 14670544.

  28. Veenema RJ, Dean AL Jr, Uson AC, Roberts M, Longo F. T Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. J Urol.1969; 101(5):711-5. Citado en PubMed; PMID: 4976352.

  29. Schuman C, Sylvester R, Robinson M. Chimiotherapie adjurante des carcinomas T1 de la vessie par instillation. Resultate preliminaries d^une etude randomisses du groupe urologique de l’EORTC. J Urol Nephrol. 1979;85:189.

  30. Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Amer. 2000;27(1):127. Citado en PubMed; PMID: 10696251.

  31. Prieto JJ, Bertelsen P. Resultado a largo plazo del tratamiento del cáncer vesical superficial con doxorrubicina endovesical. Rev Chil Urol. 2002;67(1):67-70.

  32. Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24(4):344-8. Citado en PubMed; PMID: 16818189.

  33. Witjes, JA, Hendricksen K, Gofrit O. Intravesical hipertermia and MMC for (BCG refractory) CIS of the urinary bladder. Eur Urol. 2007;6(Suppl 150):60.

  34. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P. Phase II trial of intravesical gemcitabine in bacilli Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol [Internet]. 2006 [citado 23 Abr 2012];24(18):2729-34. Disponible en: http://jco.ascopubs.org/content/24/18/2729.full?sid=1c3b553d-0588-4a48-bbc0-6427f6c8c6f9.

  35. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006; 7(1):43-51. Citado en PubMed; PMID: 16389183.

  36. Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol. 2008; 53(5):984-91. Citado en PubMed; PMID: 18248876.

  37. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52(4):1123-9. Citado en PubMed; PMID: 17383080.

  38. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100(1):33-6. Citado en PubMed; PMID: 17552951.

  39. McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24(19):3075-80. Citado en PubMed; PMID: 16809732.

  40. Gacci M, Bartoletti R, Cai T, Nerozzi S, Pinzi N, Repetti F, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int. 2006;76(2):106-11. Citado en PubMed; PMID: 16493208.




2020     |     www.medigraphic.com